 |
 |
|
|
RESÚMENES AGOSTO 2007 |
Psychotic Disorders
& Antipsychotics
(Haga un click en la información del journal para acceder al resúmen)
Outcome measures in
early psychosis. Relevance of duration of untreated psychosis
Swaran P. Singh
The British Journal of Psychiatry (2007) 191:
s58-s63
Adverse effects of antipsychotics as outcome measures
Samantha Hamer, Peter M. Haddad
The British Journal of Psychiatry (2007) 191: s64-s70
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective
disorder. Randomised, controlled, open-label study
NICHOLAS A. KEKS, MICHAEL INGHAM, AKBAR KHAN and KEITH KARCHER
The British Journal of Psychiatry (2007) 191: 131-139
Atypical
Antipsychotic Administration During Late Pregnancy:
Placental Passage and Obstetrical Outcomes
D. Jeffrey Newport, Martha R. Calamaras, C.
Lindsay DeVane, Jennifer Donovan, Aquila J. Beach,
Stephanie Winn, Bettina T. Knight, Bryan B. Gibson, Adele C. Viguera, Michael J. Owens, Charles B. Nemeroff,
and Zachary N. Stowe
Am J Psychiatry
164:1214-1220, August 2007
Cerebro- and cardiovascular conditions
in adults with schizophrenia treated with antipsychotic medications
Jeanette M. Jerrell,
Roger S. McIntyre
Human
Psychopharmacology: Clinical and Experimental. Volume 22,
Issue 6, Pages 361 - 364
Tardive dyskinesia
and glucid metabolism
Georges Brousse, Alexandre Meary, Jacques Mouret, Olivier Blanc, Thierry Hueber,
Philippe Lemoine, Pierre-Michel Llorca,
Bernard Lachaux
Human
Psychopharmacology: Clinical and Experimental. Volume 22,
Issue 6, Pages 373 - 380
Long-term administration of the low-dose risperidone in schizotaxia
subjects
Janusz K. Rybakowski,
Wiktor Drozdz, Alina Borkowska
Human
Psychopharmacology: Clinical and Experimental. Volume 22,
Issue 6, Pages 407 - 412
Add-on
Therapy With Acetylcholinesterase
Inhibitors for Memory Dysfunction in Schizophrenia: A Systematic Quantitative
Review, Part 2
Stip, Emmanuel; Sepehry, Amir Ali; Chouinard, Sylvie
Clinical Neuropharmacology. 30(4):218-229, July/August 2007
Incidence of Schizophrenia in
a Nationwide Cohort of Patients With Type 1 Diabetes
Mellitus
Hannu Juvonen,
Antti Reunanen, Jari Haukka, Maria Muhonen, Jaana Suvisaari, Ritva Arajärvi, Timo Partonen, Jouko Lönnqvist
Arch Gen Psychiatry. 2007;64:894-899
The Role of
One-Carbon Metabolism in Schizophrenia and Depression
Frances Rachel Frankenburg
Harvard Review of
Psychiatry, Volume 15, Issue 4 July 2007 , pages 146 -
160
Anticholinergic
use in hospitalised schizophrenic patients in Belgium
Marc De Hert, Martien Wampers, Ruud van Winkel and Jozef
Peuskens
Psychiatry
Research.
Volume 152, Issues 2-3, 30 August 2007, Pages 165-172
Sexual Dysfunction in
Psychiatric Inpatients The Role of Antipsychotic
Medication
J. Westheide, S. Cohen, S. Bender, D. Cooper-Mahkorn, A. Erfurth,
M. Gastpar, T. J. Huber,
W. Maier, A. Murafi, M. Rothermund, J. Signerski,
B. Sträter, L. Teusch,
W. Weig, A. Welling, K.-U. Kühn
Pharmacopsychiatry 2007; 40: 140-145
Memantine-associated Reversal of Clozapine-induced Weight Gain
M. Schaefer, K. Leopold, A. Hinzpeter, A. Heinz,
M. Krebs
Pharmacopsychiatry 2007; 40: 149-151
Worsening of
psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the
European Schizophrenia Outpatient Health Outcomes study
Diederik E. Tenback, Peter N. van Harten, Cees J. Slooff, Jim van Os and
SOHO Study Group
Comprehensive
Psychiatry. Volume 48, Issue 5, September-October 2007, Pages 436-440
Depot
Haloperidol Treatment in Outpatients With
Schizophrenia on Monotherapy: Impact of CYP2D6
Polymorphism on Pharmacokinetics and Treatment Outcome
Panagiotidis, Georgios; Arthur, Holger W; Lindh, Jonatan D; Dahl, Marja-Liisa; Sjoqvist, Folke
Therapeutic
Drug Monitoring. 29(4):417-422, August 2007
Longer Time to
Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better
Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder
Eduardo Dunayevich,
Haya Ascher-Svanum, Fangyi Zhao, Jennie G. Jacobson, Glenn A. Phillips, Mary
Anne Dellva, and Alan I. Green
J Clin Psychiatry 2007;68:1163-1171
Equivalent
Switching Dose From Oral Risperidone
to Risperidone Long-Acting Injection: A 48-Week
Randomized, Prospective, Single-Blind Pharmacokinetic Study
Ya Mei Bai, Tzu Ting
Chen, Jen-Yeu Chen, Wen-Ho
Chang, Bojian Wu, Chih Hung
Hung, and Wen Kuo Lin
J Clin Psychiatry 2007;68:1218-1225
A randomized,
double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of
patients with acute exacerbations of schizophrenia
Joseph P. McEvoy, David G. Daniel, William H. Carson Jr., Robert D. McQuade and Ronald N. Marcus
Journal
of Psychiatric Research. Volume 41, Issue 11, December 2007, Pages 895-905
Cognitive
dimensions in first-episode schizophrenia spectrum disorders
César González-Blanch, Benedicto Crespo-Facorro, Mario Álvarez-Jiménez,
José Manuel Rodríguez-Sánchez, José María Pelayo-Terán, Rocío Pérez-Iglesias and José
Luis Vázquez-Barquero
Journal
of Psychiatric Research. Volume 41, Issue 11, December 2007, Pages 968-977
Nicotine Dependence,
Symptoms and Oxidative Stress in Male Patients with Schizophrenia
Xiang Yang Zhang, Yun Long Tan, Dong Feng Zhou,
Colin N Haile, Gui
Ying Wu, Lian Yuan Cao, Therese A Kosten and Thomas R Kosten
Neuropsychopharmacology (2007) 32, 2020–2024
Treatment with amisulpride
and olanzapine improve neuropsychological function in
schizophrenia
Ann M. Mortimer, Eileen Joyce, Krishnapillai Balasubramaniam, Prasoon C. Choudhary, Packeeruther T. Saleem, for the
SOLIANOL Study Group
Human
Psychopharmacology: Clinical and Experimental. Early View. Published Online: 9 Aug 2007
Intervals Between Hospitalisations in
Schizophrenia Patients Under Antipsychotics in
Depot-Form Versus Oral Second Generation Antipsychotics
Stefan
Gutwinski, Peter Müller, Manfred Koller
Psychiat Prax
2007; 34: 289-291
Height and body mass index
in young adulthood and risk of schizophrenia: a longitudinal study of 1 347 520
Swedish men
S. Zammit,
F. Rasmussen, B. Farahmand, D. Gunnell,
G. Lewis, P. Tynelius, G. P. Brobert
Acta Psychiatrica
Scandinavica (OnlineEarly
Articles) Aug 2007
Anxiety
symptoms in schizophrenia spectrum disorders: associations with social
function, positive and negative symptoms, hope and trauma history
P. H. Lysaker, M. P. Salyers
Acta Psychiatrica Scandinavica (OnlineEarly
Articles) Aug 2007
The Treatment of
Acute Agitation in Schizophrenia
Joseph Battaglia, Delbert G. Robinson, and Leslie Citrome
CNS
Spectr. 2007;12(8 Suppl 11):1-16
TEXTO GRATUITO
Effectiveness,
safety, and tolerability of ziprasidone for treating
schizophrenia patients undergoing usual care: A 12-month, open-label,
flexible-dose, naturalistic observational trial
Yael Ratner, Anatoly Gibel, Vladimir Yorkov and Michael S. Ritsner
The effectiveness
of ziprasidone in treating impaired quality of life
in schizophrenia: A 12-month, open-label, flexible-dose, naturalistic
observational study of patients undergoing usual care
Michael S. Ritsner, Vladimir Yorkov, Yael Ratner, Peter Soifer and Anatoly Gibel
The impact of
ω-3 fatty acids, vitamins E and C supplementation on treatment outcome and
side effects in schizophrenia patients treated with haloperidol: An open-label
pilot study
E.Y. Sivrioglu, S. Kirli, D. Sipahioglu, B. Gursoy and E. Sarandöl
Amisulpride
versus risperidone in the treatment of depression in
patients with schizophrenia: A randomized, open-label, controlled trial
Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Seung-Hyun
Lee, Jeong-Hoon Lee, Bo-Hyun Yoon, Su-Jin Yang,
Michael Y. Hwang and Jin-Sang Yoon
Clozapina, neutropenia y test de prednisona
Cristian Wulff
M
REV CHIL NEURO-PSIQUIAT 2007;45
(2): 114-119
TEXTO GRATUITO
Rethinking psychosis: the disadvantages of a dichotomous classification now
outweigh the advantages
NICK CRADDOCK, MICHAEL J. OWEN
TEXTO GRATUITO